The impact of the irinotecan (IRI) schedule on quality of life in combination with capecitabine (CAP) in first-line treatment of metastatic colorectal cancer (MCC): A randomized phase II trial of the Swiss Group for Clinical Cancer Research
Markus Borner(University of Bern), A Roth(Helios Klinikum Emil von Behring), Damien Dietrich(University Hospital of Bern), Piercarlo Saletti(Institute of Oncology Research), R. Popescu(Swiss Group For Clinical Cancer Research), Richard Herrmann(New York State Department of Health), Daniel Rauch(Washington University in St. Louis), J. Bernhard(International Breast Cancer Study Group), Martin Wernli(Kantonsspital Aarau)
Cited by 9
Related Papers
Induction chemoradiation in stage IIIA/N2 non-small-cell lung cancer: a phase 3 randomised trial
|The Lancet|2015|392
Impact of comorbidities on overall survival in patients with chronic myeloid leukemia: results of the randomized CML Study IV
|Blood|2015|200
Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial
|The Lancet Respiratory Medicine|2017|184
Clinical Features, Treatment and Outcome in a Series of 93 Patients with Low-Grade Gastric MALT Lymphoma
|Leukemia & lymphoma/Leukemia and lymphoma|1997|178